latest news releases from the newsroom
U-Haul International, Inc.
Photo Release -- Elusive Goshawk Raptor Revealed At U-Haul Unveiling Event
ANCHORAGE, Alaska, May 7, 2007 (PRIME NEWSWIRE) -- U-Haul today announced the release of 1,800 new 26-foot moving vans depicting the northern goshawk in the majestic Tongass National Forest in Alaska. The Tongass National Forest is the rarest, most majestic type of forest found on Earth, and is home to many species of wildlife, including the goshawk raptor. The northern goshawk is one of several hundred species making its home in this increasingly rare, remote mixture of mountain peaks, glaciers and rivers. Legendary for their fierceness, beauty and remarkable flight skills, northern goshawks rule the Tongass.
Legacy Reserves LP
Legacy Reserves LP to Acquire Oil and Natural Gas Producing Properties for $12.9 Million
MIDLAND, Texas, May 7, 2007 (PRIME NEWSWIRE) -- Legacy Reserves LP (Nasdaq:LGCY) today announced that it has signed a definitive purchase agreement to acquire certain oil and natural gas producing properties from private parties for a purchase price of $12.9 million, subject to customary purchase price adjustments, to be paid in cash. The properties are located in the Slaughter and Rocker A fields in Cochran and Garza counties, respectively, in West Texas. The acquisition is subject to customary closing conditions and is expected to close during June.
Aastrom Biosciences, Inc.
FDA Approves Aastrom Phase III IND for Treatment of Osteonecrosis of the Femoral Head
ANN ARBOR, Mich., May 7, 2007 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a regenerative medicine company, today announced that the U.S. Food & Drug Administration (FDA) approved the Company's Investigational New Drug (IND) application to initiate a 120 patient Phase III clinical trial for the treatment of osteonecrosis (also known as avascular necrosis) of the femoral head. Aastrom intends this to be a pivotal trial with the goal of demonstrating clinical safety and efficacy for the submission of a Biologics License Application (BLA). In addition, the Company may have to generate further patient data in this indication, such as data from the ongoing pivotal trial in Spain, to support a U.S. BLA submission. Osteonecrosis is a progressive disease, with no established effective treatments, that often leads to a total hip replacement. Aastrom will use its Bone Repair Cell (BRC) product, based on Tissue Repair Cell (TRC) Technology, to evaluate this approach for treating patients suffering from osteonecrosis.
Pride International, Inc.
Pride International, Inc. Reports Record Financial Results in First Quarter 2007 Driven by Strong Operational Performance
HOUSTON, May 7, 2007 (PRIME NEWSWIRE) -- Pride International, Inc. (NYSE:PDE) today reported net income for the three months ended March 31, 2007 of $101.7 million, or $0.58 per diluted share, on revenues of $712.0 million. The results compare to net income of $70.5 million, or $0.41 per diluted share, on revenues of $566.9 million for the corresponding three months in 2006. Results for the corresponding quarter in 2006 included gains from the sale of assets totaling $26.7 million, or $0.10 per diluted share on an after-tax basis.
Bexil Corporation Announces Conference Call
NEW YORK, May 7, 2007 (PRIME NEWSWIRE) -- Bexil Corporation (AMEX:BXL) today announced that immediately following the annual meeting of stockholders, a conference call to discuss the recent results of the Company and other matters will take place on May 11, 2007 at 11:10 a.m., Eastern Time. Company executives will make a presentation and respond to questions.